Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
Primary purpose: Compare the changes in liver triglycerides concentration in the Aramchol
versus the placebo arm following three month treatment.
Secondary purpose: Comparing liver enzymes, markers of endothelial dysfunction, insulin
resistance, SCD1 activity and cholesterol synthesis and lipid levels, between the Aramchol
and the placebo arms.
Phase:
Phase 2
Details
Lead Sponsor:
Galmed Medical Reserch
Collaborators:
Beilinson Hospital, Petach Tikva,Israel Hadassah Medical Organization Hillel Yaffe Medical Center Holy Family Hospital, Nazareth, Israel Kaplan Hospital ,Rehovot,Israel Meir Medical Center Rambam Hospital, Haifa, Israel Soroka Hospital,Beer Sheva,Israel Tel-Aviv Sourasky Medical Center The Lady Davis Carmel Medical Center Ziv Hospital